Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas? Journal Article

  


Authors: Catalanotti, F.; Solit, D. B.
Article Title: Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?
Abstract: The RAF inhibitor vemurafenib has unprecedented activity in BRAF-mutant melanomas, but resistance invariably develops. As Hsp90 is required for the stability of several of the oncoproteins that mediate RAF inhibitor resistance, inhibitors of this cellular chaperone may be effective in patients with intrinsic or acquired resistance to RAF inhibitors. ©2012 AACR.
Keywords: signal transduction; cancer chemotherapy; cancer survival; unclassified drug; gene mutation; cancer growth; drug efficacy; treatment duration; antineoplastic agent; cell proliferation; animals; cell death; gene overexpression; melanoma; breast cancer; lung non small cell cancer; enzyme activation; drug resistance, neoplasm; cancer resistance; gene expression regulation; drug mechanism; heat shock protein 90 inhibitor; tanespimycin; hsp90 heat-shock proteins; drug bioavailability; b raf kinase; drug binding; proto-oncogene proteins b-raf; radicicol; retaspimycin; vemurafenib; xl 888; azabicyclo compounds; phthalic acids
Journal Title: Clinical Cancer Research
Volume: 18
Issue: 9
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2012-05-01
Start Page: 2420
End Page: 2422
Language: English
DOI: 10.1158/1078-0432.ccr-12-0626
PROVIDER: scopus
PUBMED: 22442059
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84860536638&partnerID=40&md5=632f9c38b39a25e68372e083b66c839d
Notes: --- - "Export Date: 4 June 2012" - "CODEN: CCREF" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. David Solit
    779 Solit
  2. Federica Catalanotti
    13 Catalanotti
Related MSK Work